Ferring profits drop in year of key approvals

Privately-held Swiss drugmaker Ferring was responsible for two out of the eight biological medicines approved by the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research in 2022.

The company can therefore point to major evidence of its innovative approach, with the approvals of Rebyota (fecal microbiota, live – jslm), a new microbiome treatment, and Adstiladrin (nadofaragene firadenovec-vncg), a novel gene-based therapy for bladder cancer, showing a company capable of achieving important breakthroughs.

But they represent mid- to long-term growth and diversification opportunities for Ferring, meaning it may take time for the products to make a major contribution to a balance sheet that would benefit from new revenue sources, according to figures presented on Thursday.